DCM
APRE icon

DAFNA Capital Management’s Aprea Therapeutics APRE Stock Holding History

DAFNA Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-137,174
Closed -$202K – 78
2025
Q3 		$202K Hold
137,174
– – 0.05% 75
2025
Q2 		$232K Hold
137,174
– – 0.06% 73
2025
Q1 		$280K Hold
137,174
– – 0.08% 78
2024
Q4 		$451K Hold
137,174
– – 0.11% 74
2024
Q3 		$377K Hold
137,174
– – 0.09% 75
2024
Q2 		$558K Hold
137,174
– – 0.13% 73
2024
Q1 		$918K Buy
+137,174
New +$853K 0.21% 62

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAFNA Capital Management's APRE Position: Q4 2025 in Review

DAFNA Capital Management sold out of Aprea Therapeutics (APRE) in Q4 2025, closing a stake of 137,174 shares — an estimated $202K sold.

DAFNA Capital Management first reported a position in APRE in Q1 2024 and held it in 7 quarters. The position peaked at $918K in Q1 2024. 22 funds tracked by Wall St. Rank hold APRE as of Q4 2025.

  • DAFNA Capital Management reported no remaining Aprea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 137,174 Aprea Therapeutics shares in Q4 2025, an estimated $202K.
  • DAFNA Capital Management first reported a position in Aprea Therapeutics in Q1 2024 and held it in 7 quarters.
  • DAFNA Capital Management's Aprea Therapeutics position peaked at $918K in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2025.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.